Text Only Off

Experts from Vanderbilt-Ingram to Have Voice at ASCO National Meeting

More than 25,000 cancer specialists from around the world will gather at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), June 2-6, in Atlanta, and several physicians from Vanderbilt-Ingram Cancer Center will be among them.

Nearly a dozen Vanderbilt researchers will present abstracts at the annual meeting, covering the latest advancements in treating colorectal cancer, head and neck cancer, breast cancer, lung cancer and lymphoma, among other cancer topics.

David Johnson, M.D., deputy director of the Vanderbilt-Ingram Cancer Center, will conclude his term as past-President of ASCO, while Bruce Roth, M.D., professor of Medicine and Urologic Surgery, will begin serving his term as secretary-treasurer of the national organization.

Roth will also chair an educational session on integrating chemotherapy into the management of muscle invasive bladder cancer.

Raymond DuBois, M.D., Ph.D., director of the Vanderbilt-Ingram Cancer Center, will participate in a special ASCO session with the European Cancer Societies Symposium on inflammation in cancer progression.

Mace Rothenberg, M.D., Ingram Professor of Cancer Research, and Yu Shyr, Ph.D., will participate in an educational session on integrating evidence from clinical and lab studies.

Barbara Murphy, M.D., director of the Pain and Symptom Management Program and the Head and Neck Research Program, will chair the educational session on chemoradiation for head and neck cancer, including discussion of patient selection, supportive medical care and speech and swallowing rehabilitation.

Jordan Berlin, M.D., clinical director of Gastrointestinal Oncology, will speak during a special "Meet the Professor" session on adjuvant therapy for pancreatic cancer.

David Carbone, M.D., Ph.D., Harold L. Moses Chair in Cancer Research and Ingram Professor of Cancer Research, will participate in an educational session on epidermal growth factor receptor and vascular endothelial growth factor in lung cancer and the prognostic and therapeutic impact.

Carlos Arteaga, M.D., Vice Chancellor's Chair in Breast Cancer Research and Director of Vanderbilt’s Specialized Program of Research Excellence in Breast Cancer, will chair the clinical science symposia on epidermal growth factor receptor biomarkers in lung cancer.

More than 4,000 abstracts from cancer centers across the country have been accepted to be presented at the meeting.

For the latest info from the ASCO meeting geared for cancer patients, survivors and other consumers, visit www.plwc.org.